New ICH Guideline Marks Turning Point In Supporting Multi-Regional Pediatric Development
Executive Summary
A new high-level draft ICH guideline issued is expected to reduce the likelihood of substantial differences among regions regarding acceptance of data generated in pediatric global drug development.
You may also be interested in...
ICH Expansion To Bring New Challenges For Global Consensus On Pediatric Extrapolation
The pharmaceutical industry is cautiously optimistic about the ambitious three-year timeline decided by the International Council for Harmonisation for its new guideline on pediatric extrapolation. However, ensuring consensus on this fast-developing concept will be a challenge as more regulators will have a seat at the discussion table as ICH expands.
Final ICH Addendum Offers Latest Perspectives On Pediatric Drug Development
A new document that complements the International Council for Harmonisation's existing guideline on pediatric clinical trials is expected to reduce the likelihood of significant differences among countries on the acceptance of data generated in pediatric global drug development programs
Industry Sees Little Benefit Of New EU Clinical Trial Rules On Information Materials For Minors
The European pharmaceutical industry trade group, EFPIA, is concerned about new requirements proposed in a draft European Commission guideline about how sponsors should prepare and test information materials used for obtaining informed consent from minors participating in clinical trials. It has, however, welcomed proposed changes on the use of a “staggered approach” to recruiting minors into trials.